Drug intelligence / Profile preview

Extremecare (IBCC Oncologia)

Development stage: Unknown
Lead developer: Instituto Brasileiro de Controle do Câncer
Administration: Topical

Overview

**Extremecare** is a topical moisturizing cream developed for skin care in oncology patients, including prevention of capecitabine-associated hand-foot syndrome. Its formulation contains multiple moisturizing, emollient, botanical, and antioxidant components, including glycerin, hazelnut oil, calendula oil, shea butter, chamomile, oat extract, Aloe vera, vitamin E, and Thoitaine. It does not have a defined receptor-mediated pharmacologic mechanism; its intended action is to support skin-barrier hydration, reduce dryness and desquamation, and improve comfort in treatment-affected skin. Extremecare was evaluated in the Phase 2 randomized, placebo-controlled TACX Care trial in patients receiving capecitabine.

Brand names: Extremecare

Beyond the preview

Go deeper on Extremecare (IBCC Oncologia).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Extremecare (IBCC Oncologia).

Explore the full profile